SCHEMBL22217047

SCHEMBL22217047

CC/S(=N/S(=O)(=O)c1ccc(C)cc1)c1ccc(CCl)cc1

nearest known ligand 0.70

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ LMNA P02545 3/20 0.70
▸ NPSR1 Q6W5P4 1/20 0.70
▸ CYP2C19 P33261 1/20 0.51
▸ ALDH1A1 P00352 9/20 0.48
▸ SMN1; SMN2 Q16637 3/20 0.48
▸ KMT2A Q03164 3/20 0.44
▸ MEN1 O00255 2/20 0.44
▸ RECQL P46063 1/20 0.44
▸ PIR O00625 1/20 0.43
▸ KDM4E B2RXH2 1/20 0.42
▸ MAPT P10636 1/20 0.42
▸ TDP1 Q9NUW8 1/20 0.42
▸ CYP1A2 P05177 1/20 0.37
▸ CYP2C9 P11712 1/20 0.37
▸ F2 P00734 1/20 0.36
▸ PRSS1 P07477 1/20 0.36
▸ PRSS2 P07478 1/20 0.36
▸ PRSS3 P35030 1/20 0.36
▸ HTT P42858 1/20 0.35
▸ GAA P10253 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22217048 1.00 LMNA (0.70) LMNANPSR1CYP2C19ALDH1A1SMN1; SMN2
SCHEMBL22217121 0.83 CYP2C19 (0.77) LMNANPSR1CYP2C19ALDH1A1SMN1; SMN2
SCHEMBL22217122 0.83 CYP2C19 (0.77) LMNANPSR1CYP2C19ALDH1A1SMN1; SMN2
SCHEMBL17996450 0.82 LMNA (1.00) LMNANPSR1CYP2C19ALDH1A1SMN1; SMN2
SCHEMBL22217081 0.74 ALDH1A1 (0.42) LMNANPSR1CYP2C19ALDH1A1SMN1; SMN2
SCHEMBL2282918 0.72 SMN1; SMN2 (0.67) LMNANPSR1CYP2C19ALDH1A1SMN1; SMN2
SCHEMBL20323486 0.72 F2 (0.41) LMNACYP2C19ALDH1A1SMN1; SMN2KMT2A
SCHEMBL17996448 0.72 LMNA (0.80) LMNANPSR1CYP2C19ALDH1A1SMN1; SMN2
SCHEMBL3149489 0.71 LMNA (0.74) LMNANPSR1CYP2C19ALDH1A1SMN1; SMN2
SCHEMBL17996449 0.70 LMNA (0.76) LMNANPSR1CYP2C19ALDH1A1SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12030871-B2 Pyran dervatives as CYP11A1 (cytochrome P450 monooxygenase 11A1) inhibitors ORION CORPORATION (FI) 2024-07-09 — — US disclosed
US-20210347765-A1 PYRAN DERVATIVES AS CYP11A1 (CYTOCHROME P450 MONOOXYGENASE 11A1) INHIBITORS ORION CORPORATION 2021-11-11 — — US disclosed
EP-3558981-B1 PYRAN DERIVATIVES AS CYP11A1 (CYTOCHROME P450 MONOOXYGENASE 11A1) INHIBITORS ORION CORP (FI) 2021-05-26 — — EP disclosed
US-20200299280-A1 PYRAN DERVATIVES AS CYP11A1 (CYTOCHROME P450 MONOOXYGENASE 11A1) INHIBITORS ORION CORP (FI) 2020-09-24 — — US disclosed
US-10717726-B2 Pyran dervatives as CYP11A1 (cytochrome P450 monooxygenase 11A1) inhibitors ORION CORPORATION (FI) 2020-07-21 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10717726-B2 Pyran dervatives as CYP11A1 (cytochrome P450 monooxygenase 11A1) inhibitors CYP11B1, CYP11B2, CYP4A11 LMNA 2856/4885NPSR1 703/4885CYP2C19 38/4885
US-20210347765-A1 PYRAN DERVATIVES AS CYP11A1 (CYTOCHROME P450 MONOOXYGENASE 11A1) INHIBITORS CYP11B1, CYP11B2, CYP4A11 LMNA 2856/4885NPSR1 703/4885CYP2C19 38/4885
US-12030871-B2 Pyran dervatives as CYP11A1 (cytochrome P450 monooxygenase 11A1) inhibitors CYP11B1, CYP11B2, CYP4A11 LMNA 2856/4885NPSR1 703/4885CYP2C19 38/4885
US-20200299280-A1 PYRAN DERVATIVES AS CYP11A1 (CYTOCHROME P450 MONOOXYGENASE 11A1) INHIBITORS CYP11B1, CYP11B2, CYP4A11 LMNA 2856/4885NPSR1 703/4885CYP2C19 38/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback